

Alameda Alliance for Health
1240 South Loop Road
Alameda, CA 94502

Location: Cisco Webex, (408)418-9388
Meeting ID: 146 171 2791
Password: AAHPharmacy

IMPORTANT PUBLIC HEALTH AND SAFETY MESSAGE REGARDING PARTICIPATION AT ALAMEDA ALLIANCE FOR HEALTH COMMITTEE MEETINGS

AS A RESULT OF THE COVID-19 VIRUS, AND RESULTING ORDERS AND DIRECTION FROM THE PRESIDENT OF THE UNITED STATES, THE GOVERNOR OF THE STATE OF CALIFORNIA, AND THE ALAMEDA COUNTY HEALTH OFFICER, THE PUBLIC WILL NOT BE PERMITTED TO PHYSICALLY ATTEND THE ALAMEDA ALLIANCE FOR HEALTH MEETING TO WHICH THIS AGENDA APPLIES.

YOU MAY SUBMIT COMMENTS ON ANY AGENDA ITEM OR ON ANY ITEM NOT ON THE AGENDA, IN WRITING VIA MAIL TO "ATTN: ALLIANCE PHARMACEUTICAL AND THERAPEUTICS COMMITTEE" 1240 SOUTH LOOP ROAD, ALAMEDA, CA 94502; OR THROUGH E-COMMENT AT aragadio@alamedaalliance.org. YOU MAY WATCH THE MEETING LIVE BY LOGGING IN VIA COMPUTER AT THE FOLLOWING LINK <https://alamedaalliance.webex.com/alamedaalliance> OR MAY LISTEN TO THE MEETING BY CALLING IN TO THE FOLLOWING TELEPHONE NUMBER: 1-408-418-9388. IF YOU USE THE LINK AND PARTICIPATE VIA COMPUTER, YOU MAY, THROUGH THE USE OF THE CHAT FUNCTION, REQUEST AN OPPORTUNITY TO SPEAK ON ANY AGENDIZED ITEM, INCLUDING GENERAL PUBLIC COMMENT. YOUR REQUEST TO SPEAK MUST BE RECEIVED BEFORE THE ITEM IS CALLED ON THE AGENDA. IF YOU PARTICIPATE BY TELEPHONE, YOU MUST SUBMIT ANY COMMENTS VIA THE E-COMMENT EMAIL ADDRESS DESCRIBED ABOVE.

PLEASE NOTE: THE ALAMEDA ALLIANCE FOR HEALTH IS MAKING EVERY EFFORT TO FOLLOW THE SPIRIT AND INTENT OF THE BROWN ACT AND OTHER APPLICABLE LAWS REGULATING THE CONDUCT OF PUBLIC MEETINGS, IN ORDER TO MAXIMIZE TRANSPARENCY AND PUBLIC ACCESS. IT WOULD BE APPRECIATED IF COMMUNICATIONS OF PUBLIC COMMENTS RELATED TO ITEMS ON THE AGENDA, OR ITEMS NOT ON THE AGENDA, ARE PROVIDED PRIOR TO THE COMMENCEMENT OF THE MEETING. IF THAT IS NOT POSSIBLE, EVERY EFFORT WILL BE MADE TO ATTEMPT TO REVIEW E-COMMENTS DURING THE COURSE OF THE MEETING. TOWARDS THIS END, THE CHAIR OF THE COMMITTEE WILL ENDEAVOR TO TAKE A BRIEF PAUSE BEFORE ACTION IS TAKEN ON ANY AGENDA ITEM TO ALLOW THE COMMITTEE CLERK TO REVIEW E-COMMENTS, AND SHARE ANY E-COMMENTS RECEIVED DURING THE MEETING.

AGENDA

ITEM	DESCRIPTION	TIME	VOTE
I)	Call to order <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i>		
	<ul style="list-style-type: none"> Conflict of Interest Check/Disclosure Agenda Overview 	2 min	-
II)	Informational Updates <i>Steve O'Brien, MD, Chief Medical Officer - Alameda Alliance</i> <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i>		
	<ul style="list-style-type: none"> Pharmacy Carve Out LTC at Home Upcoming audits update 	15 min	-
III)	Pharmacy Utilization Reports (Quarter 2) <i>Helen Lee, PharmD MBA, Senior Pharmacy Director – Alameda Alliance</i>		
	<ul style="list-style-type: none"> Top 50 Drugs by Cost Top 100 PA Reviewed Drugs 	2 min	-

IV) E-Voting Material/Consent Agenda

The following items have been sent to the voting committee for review via E-voting

Natalee Felten, PharmD, Pharmacist, PerformRx

(All matters listed on the Consent Calendar are to be approved with one motion unless a member of the P&T Committee removes an item for separate action. Any consent calendar item for which separate action is requested shall be heard as the next Agenda item in closed session.)

Monographs/Class Reviews	Changes
Antitubercular Agents	• No change
Ophthalmic steroids	• No change
Medication Request Guidelines	Changes
Desvenlafaxine succinate (Pristiq)	• Add psychiatrist to the prescriber restrictions section
Diclofenac sodium (Solaraze) 3% gel	• Add in brand/generic names for formulary alternatives
Hepatitis B Drugs	• Add “any other new agents” under medications section
Pregabalin (Lyrica and Lyrica CR)	• No Change
Sedative Hypnotics	• Update brand/generic status of Silenor
Makena	• No Change
Multaq (dronedarone)	• No Change
Lipotropics	• No Change
Malaria prophylaxis and treatment	• No Change
Moxifloxacin Oral Tablet	• No Change
Raloxifene (Evista)	• No Change
Constipation agents	• No Change
Dronabinol	• No Change
Opioid Dependency Agents	• No Change
Anti-Obesity Medications	• Minor grammar changes in criteria statement
Pediculicides	• Remove Ulefsia from the criteria. Discontinued as of September
Memantine ER (Namenda XR)	• No Change
Nuedexta	• No Change
Physician Administered Medication (PAD)/ Medical Benefit Guidelines	• No change
Off-label uses	• No change
Non-Formulary and PA Required Medications without Drug-Specific Criteria	• No change
Santyl Ointment	• No change
Interim Formulary changes	
	• See p. XX in packet

10
min

EV
(on
each
topic)

Pharmacy Policy & Procedure Updates

- RX010 – AAH will identify claims data issues & collaborate with internal staff and providers

P&T Meeting Minutes

- P&T Meeting Minutes Q2 March 17, 2020

ADJOURN TO CLOSED SESSION (*Pursuant to California Government Code Title 5, §54954.5(h)*)

*Discussion will Concern: Review and Recommendations to changes to the AAH Formulary and utilization management for selected drug classes
Estimated Date of Public Disclosure: 9/15/2020 (formulary changes only; no trade secrets will be disclosed).*

V) New Business

Natalee Felten, PharmD, Pharmacist, PerformRx

- Botulinum toxin Medication Request Guideline
- Physician Administered Drug (PAD) Medication Request Guideline Document

New

- Adakveo
- Injectable/Infusible Agents for Osteoporosis and Paget’s Disease
- Exondys 51

Revised

- Erythropoiesis-Stimulating Agents
- White Blood Cell Stimulators
- Iron-containing products
- Specialty Biological Agents for Crohn’s Disease
- Specialty Biological Agents for Ulcerative Colitis
- Specialty Biological Agents for Rheumatoid Arthritis
- Specialty Biological Agents for Psoriatic Arthritis (PsA)
- Specialty Biological Agents for Psoriasis
- Specialty Biological Agents for Non-FDA Approved Medically Accepted Indications
- Specialty Biological Agents for Ankylosing Spondylitis

45
min

V
(on
each
topic)

VI) Class Reviews, Monographs, and Recommendations

Natalee Felten, PharmD, Pharmacist, PerformRx

1. Oral and Topical Antivirals
2. Ulcerative colitis
3. Chelating Agents
4. Nexletol monograph
5. Nexlizet monograph
6. Oriahnn monograph

VII) Medication Request Guidelines

Rahel Negash, PharmD, Pharmacist, Alameda Alliance

Natalee Felten, PharmD, Pharmacist, PerformRx

1. Diabetes Medications Diabetes Medications used for Heart Failure
2. Antiemetics
3. FreeStyle Libre
4. Vancomycin
5. Erythropoiesis-Stimulating Agents
6. White Blood Cell Stimulators
7. Rifamycin Antibiotics
8. Injectable/Infusible Agents for Osteoporosis and Paget’s Disease
9. Injectable/Infusible Bone-Modifying Agents for Oncology Indications
10. Orilissa (elagolix)
11. Spravato (esketamine) Intranasal
12. Intranasal Steroids
13. Injectable Atypical Antipsychotic Medications
14. Inhaler Assistant Devices

VIII) Summary of Closed Session

Helen Lee, PharmD, MBA, Senior Pharmacy Director – Alameda Alliance

RECONVENE IN OPEN SESSION

ITEM	DESCRIPTION	TIME	VOTE
IX)	Informational Updates on New Developments in Pharmacy <i>Natalee Felten, PharmD, Pharmacist, PerformRx</i>	2 min	-
	<ul style="list-style-type: none"> • New Product Review 		
X)	Old Business	0 min	
	<ul style="list-style-type: none"> • None 		
XI)	Public Comment	0 min	-
XII)	Adjournment		
	<ul style="list-style-type: none"> • P&T Committee Member Forms 		

ACTION / FOLLOW-UP ITEMS		
ITEM	DUE DATE	RESPONSIBLE

FUTURE P&T MEETINGS	
NEXT MEETING	2021 P&T MEETINGS
December 15th, 2020	March 16th, 2021
	June 15 th , 2021

The Alameda Alliance for Health Pharmacy & Therapeutics Committee welcomes you to its meetings and your interest is appreciated. If you wish to speak on a matter on the agenda, you will have the opportunity to do so in the order determined by the Chair. If you wish to speak on a matter not on the agenda, please wait until the Chair asks for public comments at the end of the regular agenda. Please be brief and limit your comments to the specific subject under discussion.

Note: Only matters within the jurisdiction of the Alameda Alliance for Health Pharmacy & Therapeutics Committee may be addressed. If necessary, the Chair may limit the total time to be devoted to public comment on any item, and the time allotted to individual speakers, to ensure sufficient time for the consideration of all matters on the agenda.

This meeting is wheelchair accessible. Please contact Helen Lee at 510-747- 6241 or hlee@alamedaalliance.org at least 72 hours before the meeting to request agenda materials in an alternative format, or any other reasonable disability-related accommodations or services that may be necessary for you to participate in and enjoy the benefits of the meeting.